SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001654954-20-008470
Filing Date
2020-08-05
Accepted
2020-08-05 16:25:34
Documents
3
Period of Report
2020-08-05
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT azrx8k_aug52020.htm 8-K 32643
2 AMENDED AND RESTATED BYLAWS ex3-1.htm EX-3.1 142234
3 SUMMARY COMPARISON ex99-1.htm EX-99.1 61589
  Complete submission text file 0001654954-20-008470.txt   237806
Mailing Address 760 PARKSIDE AVENUE SUITE 304 BROOKLYN NY 11226
Business Address 760 PARKSIDE AVENUE SUITE 304 BROOKLYN NY 11226 646-699-7855
AzurRx BioPharma, Inc. (Filer) CIK: 0001604191 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37853 | Film No.: 201077715
SIC: 2834 Pharmaceutical Preparations